<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603330</url>
  </required_header>
  <id_info>
    <org_study_id>TJB0703P1</org_study_id>
    <nct_id>NCT00603330</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Infusion as Treatment for Steroid-Resistant Acute Graft Versus Host Disease (GVHD) or Poor Graft Function</brief_title>
  <official_title>Infusion of Mesenchymal Stem Cells as Treatment for Steroid-Resistant Grade II to IV Acute GVHD or Poor Graft Function: a Multicenter Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ziekenhuis Netwerk Antwerpen (ZNA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ-VUB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Mont-Godinne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jolimont Hospital Haine Saint Paul</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen Fabiola Children's University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present project aims at investigating the role of MSC for the treatment of patients with

      Part 1: Steroid-refractory grade II-IV acute GVHD.

      Part 2: Poor graft function (PGF)

      Part 3: Low or falling donor T-cell chimerism after allogeneic HCT.

      This is a multicenter phase II study examining the feasibility and efficacy of this approach.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1: complete recruitment Part 2: complete recruitment Part 3: recruiting
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arm 1. Efficacy of MSC infusion as treatment for steroid-resistant grade II - IV acute GVHD.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm 2. Efficacy of MSC infusion as treatment for poor graft function</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm 3. Efficacy of MSC infusion followed by donor lymphocyte infusion for preventing graft rejection in patients with low or failing donor T-cell chimerism after allogeneic HCT</measure>
    <time_frame>180 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity of MSC infusion</measure>
    <time_frame>180 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Graft-versus-host Disease</condition>
  <condition>Poor Graft Function</condition>
  <condition>Low Donor T-cell Chimerism</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSC infusion for steroid-refractory grade II-IV acute GVHD. In this arm, 4 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSC infusion for poor graft function. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MSC + DLI for poor donor T-cell chimerism after allogeneic HCT. In this arm, 2 x 10E6 MSC/Kg BW of the recipient will be injected during the first hour after thawing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cells</intervention_name>
    <description>Mesenchymal Stem Cell infusion</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patient eligibility criteria

          1. Male or female of any age.

          2. Previous allogeneic transplantation (related or unrelated donor, any degree of HLA
             matching) or autologous transplantation (for part 2 only) of HSC at any time before.

          3. Any source of HSC (marrow, PBSC, cord blood) and any conditioning regimen.

          4. Informed consent given by donor or his/her guardian if of minor age.

          5. Additional criteria for each part of the protocol:

        Part 1: MSC for steroid-refractory grade II-IV acute GVHD

          1. Allogeneic transplantation.

          2. Grade II-IV acute GVHD (see appendix A for acute GVHD grading) de novo or following
             DLI.

          3. Acute GVHD refractory to mPDN 2 mg/kg/day or equivalent, defined as

               -  progression of GVHD on day 3 after initiation of steroids

               -  no improvement of GVHD on day 7 after initiation of steroids

               -  absence of complete resolution of acute GVHD on day 14 after initiation of
                  steroids

               -  relapse of acute GVHD during or after steroid taper.

          4. Ongoing therapy with Ciclosporine or Tacrolimus at therapeutic doses.

          5. Patient may have received previously any other form of treatment for acute GVHD, but
             no new treatment started within 1 month of study entry.

        Part 2: MSC for poor graft function (PGF)

          1. Allogeneic or autologous transplantation.

          2. Cytopenia in 2 or 3 lineages:

               -  Hb &lt; 8.0 g/dL and reticulocytes &lt; 1%, with or without transfusion

               -  Plt &lt; 20,000/µL without transfusion

               -  Neutrophils &lt; 500/µL, without G-CSF administration

             OR severe cytopenia in 1 lineage:

               -  RBC transfusion dependent (if autologous transplantation; despite EPO
                  administration if allogeneic transplantation)

               -  Plt transfusion dependent

               -  Neutrophils &lt; 500/µL despite G-CSF administration

          3. Cytopenia duration ≥ 2 weeks beyond day 28 after autologous HCT, or day 42 (day 60 for
             cord blood transplantation) after allogeneic HCT.

          4. Cytopenia is not related to CMV or other infection, myelosuppressive/toxic drugs,
             renal failure, peripheral cell destruction or other identifiable cause.

          5. In case of HLA-identical related donor and full donor chimerism, patient can only be
             included if a boost of donor CD34+ cells has been unsuccessful or is not feasible.

        Part 3: MSC + DLI for poor donor T-cell chimerism

          1. Nonmyeloablative allogeneic transplantation.

          2. Donor T-cell chimerism &lt; 50% for at least 2 consecutive weeks beyond day 21 after HCT
             OR

               -  20% decrease in donor T-cell chimerism with the second value &lt; 50%.

        MSC donor inclusion criteria

          1. Related to the recipient (sibling, parent or child) or unrelated.

          2. Male or female.

          3. Age &gt; 16 yrs (no age limit if same as HSC donor).

          4. No HLA matching required.

          5. Fulfills generally accepted criteria for allogeneic HSC donation.

          6. Informed consent given by donor or his/her guardian if of minor age.

        Exclusion Criteria:

        Patient exclusion criteria

          1. HIV positive.

          2. Active uncontrolled infection at time of scheduled MSC infusion.

          3. Relapsing or progressing malignancy.

        MSC donor exclusion criteria

          1. HIV positive

          2. Known allergy to Lidocaine

          3. If donor other than HSC donor : any risk factor for transmissible infectious diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yves Beguin, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frédéric Baron, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU-ULg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johan Maertens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Katholieke Universiteit Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harry Schouten, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre Zachée, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stuyvenberg Hospital Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zwi Berneman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZA Antwerpen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucien Noens, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ-Gent</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rick Schots, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ VUB Jette</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominik Selleslag, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ St. Jan Bugge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Augustin Ferrant, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL St. Luc Brussels</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chantal Doyen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires Mont-Godinne at Yvoir</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole Straetmans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital de Jolimont at Haine-St-Paul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicole Ferster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital des enfants Reine Fabiola at Brussels</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yves Beguin, MD, PhD</last_name>
    <phone>32-4-366 72 01</phone>
    <email>yves.beguin@chu.ulg.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frederic Baron, MD, PhD</last_name>
    <phone>32-4-366 72 01</phone>
    <email>F.Baron@ulg.ac.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Edeghem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zwi Berneman, MD, PhD</last_name>
      <phone>32(03)8213250</phone>
      <email>zwi.berneman@uza.be</email>
    </contact>
    <investigator>
      <last_name>Zwi Berneman, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital des enfants Reine Fabiola</name>
      <address>
        <city>Brussels</city>
        <state>Brabant</state>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Ferster, MD</last_name>
      <phone>32(02)4773283</phone>
      <email>alice.ferster@huderf.be</email>
    </contact>
    <investigator>
      <last_name>Alice Ferster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ VUB Jette</name>
      <address>
        <city>Brussels</city>
        <state>Brabant</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rik Schots, MD, PhD</last_name>
      <phone>32 (02) 4763105</phone>
      <email>Rik.Schots@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Rick Schots, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</name>
      <address>
        <city>Brussels</city>
        <state>Brabant</state>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augustin Ferrant, MD, PhD</last_name>
      <phone>32 (02) 7641880</phone>
      <email>Augustin.Ferrant@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Augustin Ferrant, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Gasthuisberg Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flamish Brabant</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Maertens, MD</last_name>
      <phone>32- 16 33 22 11</phone>
      <email>johan.maertens@uz.kuleuven.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Koen Theunissen, MD</last_name>
      <phone>32- 16 33 22 11</phone>
      <email>koen.theunissen@uz.kuleuven.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Johan Maertens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Koen Theunissen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <state>Flanders Ost</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucien Noens, MD, PhD</last_name>
      <phone>32(09) 332 21 31</phone>
      <email>Lucien.Noens@Ugent.be</email>
    </contact>
    <investigator>
      <last_name>Lucien Noens, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Jolimont</name>
      <address>
        <city>Haine St Paul</city>
        <state>Hainaut</state>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Straetmans, MD</last_name>
      <phone>32(064) 235071</phone>
      <email>nicole.straetmans@scarlet.be</email>
    </contact>
    <investigator>
      <last_name>Nicole Straetmans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Mont-Godinne</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chantal Doyen, MD</last_name>
      <phone>32(081)423831</phone>
      <email>chantal.doyen@sang.ucl.ac.be</email>
    </contact>
    <investigator>
      <last_name>Chantal Doyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ St Jan</name>
      <address>
        <city>Brugge</city>
        <state>West Flanders</state>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domonik Selleslag, MD</last_name>
      <phone>32 (050) 453060</phone>
      <email>dominik.selleslag@azbrugge.be</email>
    </contact>
    <investigator>
      <last_name>Dominik Selleslag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Stuyvenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Zachée, MD, PhD</last_name>
      <phone>32(03)2177111</phone>
      <email>pierre.zachee@zna.be</email>
    </contact>
    <investigator>
      <last_name>Pierre Zachée, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Sart Tilman</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Beguin, MD/PhD</last_name>
      <phone>32-4-366 72 01</phone>
      <email>yves.beguin@chu.ulg.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Frederic Baron, MD/PhD</last_name>
      <phone>32-4-366 72 01</phone>
      <email>F.Baron@ulg.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Yves Beguin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederic Baron, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chantal Lechanteur, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne Baudoux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelyne Willems, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pascale Frère, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard De Prijck, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6200</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Harry Schouten, MD</last_name>
      <phone>+31-43-3876543</phone>
      <email>h.schouten@intmed.unimaas.nl</email>
    </contact>
    <investigator>
      <last_name>Harry Schouten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Liege</investigator_affiliation>
    <investigator_full_name>Yves Beguin</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal stem cells</keyword>
  <keyword>Graft-versus-host disease</keyword>
  <keyword>Poor graft function</keyword>
  <keyword>Chimerism</keyword>
  <keyword>Hematopoietic cell transplantation recipients</keyword>
  <keyword>Low donor T-cell chimerism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

